Intensive glucose control improves kidney outcomes in patients with type 2 diabetes (Q57312402)

Sophia Zoungas

16

0 references

Michel Marre

Michel Marre

10

0 references

John Chalmers

John Chalmers

3

0 references

Pavel Hamet

9

Pavel Hamet

0 references

Alan Cass

Alan Cass

14

0 references

Min Jun

Min Jun

5

0 references

Giuseppe Mancia

13

Giuseppe Mancia

0 references

Neil R Poulter

12

Neil Poulter

0 references

Anushka Patel

15

Anushka Patel

0 references

Stephen MacMahon

7

Stephen MacMahon

0 references

Carl Erik Mogensen

11

Carl Erik Mogensen

0 references

Hiddo J L Heerspink

2

Hiddo Lambers Heerspink

0 references

author name string

Mark Woodward

4

0 references

Qiang Li

6

0 references

Mark E. Cooper

https://scigraph.springernature.com/pub.10.1038/ki.2012.401

8

0 references

language of work or name

English

0 references

publication date

March 2013

0 references

published in

Kidney International

0 references

volume

83

0 references

page(s)

517-523

0 references

issue

3

0 references

exact match

0 references

cites work

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Albuminuria as a surrogate marker for drug development: a European Regulatory perspective

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Of fads, fashion, surrogate endpoints and dual RAS blockade

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Diabetic kidney disease with and without albuminuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Standards of medical care in diabetes--2011.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Reversal of lesions of diabetic nephropathy after pancreas transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.401

7 January 2021